BDX - Becton Dickinson & Co Stock Analysis
Becton Dickinson & Co (BDX) is a publicly traded company listed on the NYSE. It operates in the Medical Instruments & Supplies industry, part of the broader Healthcare sector. The company has a market capitalization of 43.91B, generates annual revenue of 21.92B, and reports net income of 1.76B. As of the latest data, the stock is trading at 154.22 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. The stock offers a moderate dividend yield (2.55%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.7), indicating current market sentiment. Institutional ownership is reported at 95.56%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -1.44%, trading within a 52-week range of 127.54 - 187.35.
BDX - Becton Dickinson & Co
154.22
Analyst Consensus
Hold 3.7
BDX – Analyst Rating Summary
- Strong Buy: 5
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
- Total Analysts: 20
| Index: | S&P 500 | P/E: | 25.19 | EPS (ttm): | 6.12 | Insider Own: | 0.19% | Shs Outstand: | 284.74M | Perf Week: | -0.19% |
| Market Cap: | 43.91B | Forward P/E: | 11.46 | EPS next Y: | 13.45 | Insider Trans: | -0.70% | Shs Float: | 284.21M | Perf Month: | -5.49% |
| Income(ttm): | 1.76B | PEG: | 1.41 | EPS next Q: | 2.78 | Inst Own: | 95.56% | Short Float: | 3.34% | Perf Quarter: | -4.35% |
| Revenue(ttm): | 21.92B | P/S: | 2.00 | EPS this Y: | 10.33% | Inst Trans: | 2.40% | Short Ratio: | 3.40 | Perf Half Y: | 1.19% |
| Book/sh: | 88.79 | P/B: | 1.74 | EPS next Y: | 7.76% | ROA: | 3.21% | Short Interest: | 9.49M | Perf Year: | -1.44% |
| Cash/sh: | 3.63 | P/C: | 42.43 | EPS next 5Y: | 8.12% | ROE: | 6.96% | 52W Range: | 127.54 - 187.35 | Perf YTD: | 1.12% |
| Dividend Est.: | 3.93 (2.55%) | P/FCF: | 16.69 | EPS past 3/5Y: | -0.35% 16.45% | ROIC: | 4.16% | 52W High: | 187.35 -17.68% | Beta: | 0.28 |
| Dividend TTM: | 3.51 (2.28%) | Quick Ratio: | 0.58 | Sales past 3/5Y: | 4.99% 6.32% | Gross Margin: | 46.07% | 52W Low: | 127.54 20.92% | Perf 5Y: | -18.81% |
| Dividend Ex-Date: | Mar 10, 2026 | Current Ratio: | 1.05 | EPS Y/Y TTM: | 1.52% | Oper. Margin: | 14.77% | RSI (14): | 38.25 | Volatility: | 1.68% 2.05% |
| Employees: | 72000 | Debt/Eq: | 0.77 | Sales Y/Y TTM: | 6.22% | Profit Margin: | 8.01% | Recom: | 2.38 | Target Price: | 189.00 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.67 | EPS Q/Q: | 28.08% | Payout: | 71.53% | Rel Volume: | 0.73 | Prev Close: | 155.46 |
| Sales Surprise: | -12.84% | EPS Surprise: | 3.48% | Sales Q/Q: | 1.63% | Earnings: | May 07 BMO | Avg Volume: | 2.79M | Price: | 154.22 |
| SMA20: | -1.52% | SMA50: | -6.77% | SMA200: | 0.79% | Undervalued: 22.55% | Volume: | 2,051,873 | Change: | -0.80% | |
Graham Classic formula value: 135.96
(P/E=8 * 1g) Min value: 88.59
(current P/E * 2g) Max value: 227.68
Average value: 150.74
About Becton Dickinson & Co
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.